Browse > Article
http://dx.doi.org/10.4110/in.2010.10.3.99

GSK3β Inhibitor Peptide Protects Mice from LPS-induced Endotoxin Shock  

Ko, Ryeojin (Division of Life and Pharmaceutical Sciences, Center for Cell Signaling & Drug Discovery Research, Ewha Womans University)
Jang, Hyun Duk (Division of Life and Pharmaceutical Sciences, Center for Cell Signaling & Drug Discovery Research, Ewha Womans University)
Lee, Soo Young (Division of Life and Pharmaceutical Sciences, Center for Cell Signaling & Drug Discovery Research, Ewha Womans University)
Publication Information
IMMUNE NETWORK / v.10, no.3, 2010 , pp. 99-103 More about this Journal
Abstract
Background: Glycogen synthase kinase $3{\beta}$ ($GSK3{\beta}$) is a ubiquitous serine/threonine kinase that is regulated by serine phosphorylation at 9. Recent studies have reported the beneficial effects of a number of the pharmacological $GSK3{\beta}$ inhibitors in rodent models of septic shock. Since most of the $GSK3{\beta}$ inhibitors are targeted at the ATP-binding site, which is highly conserved among diverse protein kinases, the development of novel non-ATP competitive $GSK3{\beta}$ inhibitors is needed. Methods: Based on the unique phosphorylation motif of $GSK3{\beta}$, we designed and generated a novel class of $GSK3{\beta}$ inhibitor (GSK3i) peptides. In addition, we investigated the effects of a GSK3i peptide on lipopolysaccharide (LPS)-stimulated cytokine production and septic shock. Mice were intraperitoneally injected with GSK3i peptide and monitored over a 7-day period for survival. Results: We first demonstrate its effects on LPS-stimulated pro-inflammatory cytokine production including interleukin (IL)-6 and IL-12p40. LPS-induced IL-6 and IL-12p40 production in macrophages was suppressed when macrophages were treated with the GSKi peptide. Administration of the GSK3i peptide potently suppressed LPS-mediated endotoxin shock. Conclusion: Collectively, we present a rational strategy for the development of a therapeutic GSK3i peptide. This peptide may serve as a novel template for the design of non-ATP competitive GSK3 inhibitors.
Keywords
$GSK3{\beta}$; Peptide inhibitor; LPS; Cytokines;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2;769-776, 2001
2 Frame S, Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359;1-16, 2001   DOI   ScienceOn
3 Woodgett JR: Judging a protein by more than its name: GSK-3. Sci STKE 2001;re12, 2001
4 Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMPdependent protein kinase and phosphorylase kinase. Eur J Biochem 107;519-527, 1980
5 Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR: Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275;1930-1934, 1997   DOI   ScienceOn
6 El Jamali A, Freund C, Rechner C, Scheidereit C, Dietz R, Bergmann MW: Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3 beta. FASEB J 18;1096-1098, 2004
7 Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr: The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8;25-33, 2005   DOI   ScienceOn
8 Gregory MA, Qi Y, Hann SR: Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278;51606-51612, 2003   DOI   ScienceOn
9 Liang J, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2; 339-345, 2003
10 Gum RJ, Gaede LL, Koterski SL, Heindel M, Clampit JE, Zinker BA, Trevillyan JM, Ulich RG, Jirousek MR, Rondinone CM: Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52;21-28, 2003   DOI   ScienceOn
11 Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Ma ST, Reeder JW, Samuels I, Slabiak T, Wagman AS, Hammond ME, Harrison SD: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52;588-595, 2003   DOI   ScienceOn
12 Martinez A, Perez DI: GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15;181-191, 2008   DOI
13 Beaulieu JM, Gainetdinov RR, Caron MG: Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49;327-347, 2009   DOI   ScienceOn
14 Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126;955-968, 2006   DOI   ScienceOn
15 Martin M, Rehani K, Jope RS, Michalek SM: Toll-like receptor- mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6;777- 784, 2005
16 Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR, Ivashkiv LB: IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24;563-574, 2006   DOI   ScienceOn
17 Wada A: GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 14;1558- 1570, 2009
18 Rehani K, Wang H, Garcia CA, Kinane DF, Martin M: Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J Immunol 182;547-553, 2009   DOI
19 Beurel E, Jope RS: Glycogen synthase kinase-3 promotes the synergistic action of interferon-gamma on lipopolysaccharide- induced IL-6 production in RAW264.7 cells. Cell Signal 21;978-985, 2009   DOI   ScienceOn
20 Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3;479-487, 2004   DOI   ScienceOn
21 Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN: GSK3beta: role in therapeutic landscape and development of modulators. Br J Phamacol 160;1-19, 2010   DOI   ScienceOn
22 Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 305;974-980, 2003   DOI   ScienceOn
23 Fischer PM: CDK versus GSK-3 inhibition: a purple haze no longer? Chem Biol 10;1144-1146, 2003   DOI   ScienceOn
24 Phiel CJ, Klein PS: Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41;789-813, 2001   DOI   ScienceOn
25 Sawa M: Strategies for the design of selective protein kinase inhibitors. Mini Rev Med Chem 8;1291-1297, 2008   DOI   ScienceOn
26 Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105;721-732, 2001   DOI   ScienceOn
27 Kim H, Choi HK, Shin JH, Kim KH, Huh JY, Lee SA, Ko CY, Kim HS, Shin HI, Lee HJ, Jeong D, Kim N, Choi Y, Lee SY: Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest 119;813-825, 2009   DOI   ScienceOn
28 Frame S, Cohen P, Biondi RM: A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7;1321- 1327, 2001   DOI   ScienceOn
29 ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J: Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 8;593-596, 2001   DOI   ScienceOn
30 Choi JM, Ahn MH, Chae WJ, Jung YG, Park JC, Song HM, Kim YE, Shin JA, Park CS, Park JW, Park TK, Lee JH, Seo BF, Kim KD, Kim ES, Lee DH, Lee SK, Lee SK: Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 12;574-579, 2006   DOI   ScienceOn
31 Beurel E, Michalek SM, Jope RS: Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 31;24-31, 2010   DOI   ScienceOn
32 Jope RS, Yuskaitis CJ, Beurel E: Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32;577-595, 2007   DOI   ScienceOn
33 Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A: Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156;885-898, 2009   DOI   ScienceOn
34 Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ, Smith DG, Reith AD: The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure 9;1143-1152, 2001   DOI   ScienceOn
35 Doble BW, Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116;1175-1186, 2003   DOI   ScienceOn
36 Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ: Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3;1009-1013, 2001   DOI   ScienceOn
37 Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, Michiels C: Regulation of hypoxia-inducible factor- 1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 278;31277- 31285, 2003   DOI   ScienceOn
38 Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378;785-789, 1995   DOI   ScienceOn
39 Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 305;974-980, 2003   DOI   ScienceOn
40 Sato AK, Viswanathan M, Kent RB, Wood CR: Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17;638-642, 2006   DOI   ScienceOn